J&J to provide U.S. with 100M doses of COVID-19 vaccine

By The Science Advisory Board staff writers

Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives regulatory approval from the U.S. Food and Drug Administration (FDA).

Funding of over $1 billion will be provided by the U.S. Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the U.S. Department of Defense. Under the agreement, the vaccine, Ad26.COV2.S, will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses under an additional agreement.

The company is conducting research and development in collaboration with BARDA and oversight from the FDA. Recently published phase I/IIa clinical trial results were positive and the company is currently evaluating both one- and two-dose regimens.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: